Search Results | Clinical Cancer Research | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Race-Dependent Differences in Risk, Genomics, and Epstein–Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120

Madhav V. Dhodapkar, Rachael Sexton, Antje Hoering, Frits Van Rhee, Bart Barlogie, Robert Orlowski

Clin Cancer Res (2020) 26 (22): 5814–5819.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-2119

Published: 13 November 2020

View article

Journal Articles

BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma

Clin Cancer Res (2020) 26 (10): 2422–2432.

DOI: https://doi.org/10.1158/1078-0432.CCR-19-1507

Published: 15 May 2020

View article

Includes: Supplementary data

Journal Articles

Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenström's Macroglobulinemia

Mu Hao, Bart Barlogie, Guido Tricot, Lanting Liu, Lugui Qiu, John D. Shaughnessy, Jr, Fenghuang Zhan

Clin Cancer Res (2019) 25 (1): 201–209.

DOI: https://doi.org/10.1158/1078-0432.CCR-18-1435

Published: 03 January 2019

View article

Includes: Supplementary data

Journal Articles

The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma

Carolina Schinke, Pingping Qu, Syed J. Mehdi, Antje Hoering, Joshua Epstein, Sarah K. Johnson, Frits van Rhee, Maurizio Zangari, Sharmilan Thanendrarajan, Bart Barlogie, Faith E. Davies, Shmuel Yaccoby, Gareth J. Morgan

Clin Cancer Res (2018) 24 (12): 2913–2919.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-2627

Published: 14 June 2018

View article

Includes: Supplementary data

Journal Articles

Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants

Clin Cancer Res (2017) 23 (11): 2665–2672.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-2620

Published: 31 May 2017

View article

Includes: Supplementary data

Journal Articles

Assessment of Total Lesion Glycolysis by ¹⁸F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma

James E. McDonald, Marcus M. Kessler, Michael W. Gardner, Amy F. Buros, James A. Ntambi, Sarah Waheed, Frits van Rhee, Maurizio Zangari, Christoph J. Heuck, Nathan Petty, Carolina Schinke, Sharmilan Thanendrarajan, Alan Mitchell, Antje Hoering, Bart Barlogie, Gareth J. Morgan, Faith E. Davies

Clin Cancer Res (2017) 23 (8): 1981–1987.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-0235

Published: 13 April 2017

View article

Includes: Supplementary data

Journal Articles

The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma

Clin Cancer Res (2016) 22 (23): 5783–5794.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-1790

Published: 30 November 2016

View article

Includes: Supplementary data

Journal Articles

Conclusions of a seven-year translational research initiative: Defining and validating a molecular signature of high-risk multiple myeloma

John Shaughnessy, Jr, Fenghuang Zhan, Bart Barington, John Crowley, Bart Barlogie

Clin Cancer Res (2007) 13 (19_Supplement): PR-2.

Published: 15 August 2014

View article

Journal Articles

Developing and Validating Continuous Genomic Signatures in Randomized Clinical Trials for Predictive Medicine

Shigeyuki Matsui, Richard Simon, Pingping Qu, John D. Shaughnessy, Jr, Bart Barlogie, John Crowley

Clin Cancer Res (2012) 18 (21): 6065–6073.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-1206

Published: 06 November 2012

View article

Journal Articles

Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Christoph J. Heuck, Jackie Szymonifka, Emily Hansen, John D. Shaughnessy, Jr, Saad Z. Usmani, Frits van Rhee, Elias Anaissie, Bijay Nair, Sarah Waheed, Yazan Alsayed, Nathan Petty, Clyde Bailey, Joshua Epstein, Antje Hoering, John Crowley, Bart Barlogie

Clin Cancer Res (2012) 18 (19): 5499–5506.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-0019

Published: 30 September 2012

View article

Includes: Supplementary data

Journal Articles

Cure Models as a Useful Statistical Tool for Analyzing Survival

Megan Othus, Bart Barlogie, Michael L. LeBlanc, John J. Crowley

Clin Cancer Res (2012) 18 (14): 3731–3736.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-2859

Published: 15 July 2012

View article

Includes: Supplementary data

Journal Articles

Tumor Cell Gene Expression Changes Following Short-term In vivo Exposure to Single Agent Chemotherapeutics are Related to Survival in Multiple Myeloma

Bart Burington, Bart Barlogie, Fenghuang Zhan, John Crowley, John D. Shaughnessy, Jr.

Clin Cancer Res (2008) 14 (15): 4821–4829.

DOI: https://doi.org/10.1158/1078-0432.CCR-07-4568

Published: 01 August 2008

View article

Includes: Supplementary data

Journal Articles

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

Clin Cancer Res (2008) 14 (9): 2775–2784.

DOI: https://doi.org/10.1158/1078-0432.CCR-07-4246

Published: 01 May 2008

View article

Journal Articles

Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling

Jeffrey Haessler, John D. Shaughnessy, Jr., Fenghuang Zhan, John Crowley, Joshua Epstein, Frits van Rhee, Elias Anaissie, Mauricio Pineda-Roman, Maurizio Zangari, Klaus Hollmig, Abid Mohiuddin, Yazan Alsayed, Antje Hoering, Guido Tricot, Bart Barlogie

Clin Cancer Res (2007) 13 (23): 7073–7079.

DOI: https://doi.org/10.1158/1078-0432.CCR-07-0527

Published: 03 December 2007

View article

Includes: Supplementary data

Journal Articles

Sydney E. Salmon

Raymond Alexanian, Kenneth Anderson, Bart Barlogie, James Berenson, William S. Dalton, Robert A. Kyle

Clin Cancer Res (2000) 6 (1): 316.

Published: 01 January 2000

View article

NARROW

Race-Dependent Differences in Risk, Genomics, and Epstein–Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120

BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma

Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenström's Macroglobulinemia

The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma

Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants

Assessment of Total Lesion Glycolysis by ¹⁸F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma

The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma

Conclusions of a seven-year translational research initiative: Defining and validating a molecular signature of high-risk multiple myeloma

Developing and Validating Continuous Genomic Signatures in Randomized Clinical Trials for Predictive Medicine

Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Cure Models as a Useful Statistical Tool for Analyzing Survival

Tumor Cell Gene Expression Changes Following Short-term In vivo Exposure to Single Agent Chemotherapeutics are Related to Survival in Multiple Myeloma

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling

Sydney E. Salmon

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only